EQT Life Sciences
Investor profile
Venture capital
EQT Life Sciences has backed 20 European tech companies across 21 funding rounds between 2022 and 2026, joining rounds totalling €1.4B. Most active in Healthtech. Data as of Nov 2026.
Also recorded as: EQT Lifesciences
Deals
21
distinct rounds
Companies
20
backed
Active span
2022–2026
5 yrs
Total round €
€1.4B
sum of rounds joined
Deals by year
distinct rounds / yearEQT Life Sciences — deals by year — interactive chart.
Data table
| EQT Life Sciences — deals by year | |
|---|---|
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 8 |
| 2026 | 4 |
Top sectors
by dealsEQT Life Sciences — top sectors — interactive chart.
Data table
| EQT Life Sciences — top sectors | |
|---|---|
| Healthtech | 21 |
Stages
by dealsEQT Life Sciences — stages — interactive chart.
Data table
| EQT Life Sciences — stages | |
|---|---|
| Series A | 5 |
| Series B | 5 |
| Series C | 4 |
| Series D+ | 4 |
| Other | 3 |
Countries
by dealsEQT Life Sciences — countries — interactive chart.
Data table
| EQT Life Sciences — countries | |
|---|---|
| Switzerland | 5 |
| Ireland | 4 |
| UK | 4 |
| Germany | 3 |
| Netherlands | 2 |
| Denmark | 1 |
| France | 1 |
| Spain | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- Andera Partners5
- Invest-NL4
- M Ventures3
- Novartis Venture Fund3
- Sofinnova Partners3
- DaVita Venture Group2
- Enterprise Ireland2
- Fountain Healthcare Partners2
- GIMV2
- imec.xpand2
- Innovation Industries2
- Novo Holdings2
- OrbiMed2
- Pfizer Ventures2
- Sanofi Ventures2
- SV Health Investors2
- Wellington Partners2
- 15th Rock1
- 5AM Ventures1
- ABV Uni Fund1
- Adjuvant Capital1
- Advent Life Sciences1
- Angelini Ventures1
- Aphelion1
- Asabys Partners1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Tubulis Technologies | Germany | 1 | €308M |
| Amolyt Pharma | France | 1 | €129M |
| Nouscom | Switzerland | 1 | €120M |
| SpliceBio | Spain | 1 | €118M |
| Artios | UK | 1 | €99M |
| ViCentra | Netherlands | 1 | €73M |
| Mosanna Therapeutics | Switzerland | 1 | €70M |
| Neurent Medical | Ireland | 1 | €63M |
| MinervaX | Denmark | 1 | €54M |
| Xeltis | Switzerland | 2 | €51M |
| Exciva | Germany | 1 | €51M |
| FoRx Therapeutics | Switzerland | 1 | €43M |
| Phagenesis | UK | 1 | €39M |
| Cyted Health | UK | 1 | €37M |
| Onera Health | Netherlands | 1 | €30M |
| Ariceum Therapeutics | Germany | 1 | €25M |
| Perfuze | Ireland | 1 | €22M |
| LUMA Vision | Ireland | 1 | €20M |
| FundamentalVR | UK | 1 | €19M |
| Nua Surgical | Ireland | 1 | €6.5M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Tubulis Technologies | Series C | €308M | 2025-10 |
| Amolyt Pharma | Series C | €129M | 2023-01 |
| SpliceBio | Series B | €118M | 2025-06 |
| Artios | Series D+ | €99M | 2025-11 |
| ViCentra | Series D+ | €73M | 2025-09 |
| Mosanna Therapeutics | Series A | €70M | 2025-06 |
| Neurent Medical | Series C | €63M | 2026-02 |
| MinervaX | Other | €54M | 2023-10 |
| Exciva | Series B | €51M | 2026-01 |
| FoRx Therapeutics | Series A | €43M | 2025-12 |